Avecho Biotechnology Completes Treatment Phase for Interim Analysis of Third-Phase Insomnia Trial
MT Newswires Live
May 21
Avecho Biotechnology (ASX:AVE) completed the treatment phase for the last patient required for the planned interim analysis of its pivotal third-phase insomnia trial evaluating its tocopheryl phosphate mixture-enhanced cannabidiol capsule, according to a Thursday filing with the Australian bourse.
The analysis is expected to provide the first indication of the product's efficacy profile, determine the number of participants needed for the final study, and support ongoing licensing discussions, the filing said.
Results are expected in late June, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.